金吾财讯 | 中国中药(00570)股价受压，截至发稿，报2.11港元，跌3.65%，成交额3.65港元。中国中药公布，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人民币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元；及本期经调整溢利净额同比下降45%至55%，上年同期约为人民币6.355亿元。大摩发布策略报告表示，相信中国中药的股价将在未来30天下跌，予其“减持”评级，目标价1.5港元。该行指，预计股价出现变动是由盈警所致，该公司预计2025年度将录得亏损，属2013年以来首见。该行相信，面对市场规模萎缩的困境，公司未透露透过内部资源拓展或并购开拓新市场的具体规划。因此，市场目前对公司2026年业绩的能见度偏低，预期股价仍有进一步下行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.